image
Thermo Fisher Scientific Inc. TMO
Healthcare - Medical - Diagnostics & Research - NYSE - US
Watchlist
$ 437.87
-0.00913 %
$ 165 B
Market Cap
26.52
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TMO stock under the worst case scenario is HIDDEN Compared to the current market price of 438 USD, Thermo Fisher Scientific Inc. is HIDDEN

TMO Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TMO stock under the base case scenario is HIDDEN Compared to the current market price of 438 USD, Thermo Fisher Scientific Inc. is HIDDEN

TMO Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TMO stock under the best case scenario is HIDDEN Compared to the current market price of 438 USD, Thermo Fisher Scientific Inc. is HIDDEN

TMO Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart TMO

image
1M -18%
6M -35%
1Y -24%
3Y -32%
5Y 39%
All
$620.0$620.0$600.0$600.0$580.0$580.0$560.0$560.0$540.0$540.0$520.0$520.0$500.0$500.0$480.0$480.0$460.0$460.0$440.0$440.0$420.0$420.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
42.9 B REVENUE
0.05%
Growth Rates
1Year 0.05%
3Years 3.03%
5Years 10.92%
7Years 10.80%
10Years 9.76%
7.34 B OPERATING INCOME
6.97%
Growth Rates
1Year 6.97%
3Years -9.89%
5Years 9.82%
7Years 13.80%
10Years 11.35%
6.34 B NET INCOME
5.72%
Growth Rates
1Year 5.72%
3Years -6.40%
5Years 11.39%
7Years 16.11%
10Years 12.83%
8.67 B OPERATING CASH FLOW
3.10%
Growth Rates
1Year 3.10%
3Years -3.16%
5Years 11.75%
7Years 11.66%
10Years 12.71%
-5.84 B INVESTING CASH FLOW
-13.59%
Growth Rates
1Year -13.59%
3Years 35.66%
5Years -31.47%
7Years 3.92%
10Years 6.78%
-6.79 B FINANCING CASH FLOW
-87.52%
Growth Rates
1Year -87.52%
3Years -26.66%
5Years -16.85%
7Years -15.62%
10Years -9.22%
11.4 B REVENUE
7.52%
Growth Rates
1Year 0.05%
3Years 3.03%
5Years 10.92%
7Years 10.80%
10Years 9.76%
2.02 B OPERATING INCOME
9.68%
Growth Rates
1Year 6.97%
3Years -9.89%
5Years 9.82%
7Years 13.80%
10Years 11.35%
1.82 B NET INCOME
11.29%
Growth Rates
1Year 5.72%
3Years -6.40%
5Years 11.39%
7Years 16.11%
10Years 12.83%
3.29 B OPERATING CASH FLOW
51.89%
Growth Rates
1Year 3.10%
3Years -3.16%
5Years 11.75%
7Years 11.66%
10Years 12.71%
20 M INVESTING CASH FLOW
100.56%
Growth Rates
1Year -13.59%
3Years 35.66%
5Years -31.47%
7Years 3.92%
10Years 6.78%
-3.67 B FINANCING CASH FLOW
-208.07%
Growth Rates
1Year -87.52%
3Years -26.66%
5Years -16.85%
7Years -15.62%
10Years -9.22%
Balance Sheet Thermo Fisher Scientific Inc.
image
Current Assets 22.1 B
Cash & Short-Term Investments 5.57 B
Receivables 8.19 B
Other Current Assets 8.38 B
Non-Current Assets 75.2 B
Long-Term Investments 0
PP&E 9.31 B
Other Non-Current Assets 65.9 B
5.72 %8.42 %8.61 %9.56 %67.69 %Total Assets$97.3b
Current Liabilities 13.3 B
Accounts Payable 0
Short-Term Debt 2.21 B
Other Current Liabilities 11.1 B
Non-Current Liabilities 34.3 B
Long-Term Debt 29.1 B
Other Non-Current Liabilities 5.26 B
4.65 %23.33 %60.99 %11.03 %Total Liabilities$47.7b
EFFICIENCY
Earnings Waterfall Thermo Fisher Scientific Inc.
image
Revenue 42.9 B
Cost Of Revenue 24.8 B
Gross Profit 18.1 B
Operating Expenses 10.7 B
Operating Income 7.34 B
Other Expenses 999 M
Net Income 6.34 B
45b45b40b40b35b35b30b30b25b25b20b20b15b15b10b10b5b5b0043b(25b)18b(11b)7b(999m)6bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
42.23% GROSS MARGIN
42.23%
Averages
1Year 42.23%
3Years 41.86%
5Years 45.68%
7Years 45.91%
10Years 46.54%
17.11% OPERATING MARGIN
17.11%
Averages
1Year 17.11%
3Years 17.27%
5Years 20.31%
7Years 19.30%
10Years 17.64%
14.77% NET MARGIN
14.77%
Averages
1Year 14.77%
3Years 14.75%
5Years 16.74%
7Years 15.75%
10Years 14.36%
12.78% ROE
12.78%
Averages
1Year 12.78%
3Years 13.81%
5Years 15.77%
7Years 14.56%
10Years 12.93%
6.51% ROA
6.51%
Averages
1Year 6.51%
3Years 6.58%
5Years 7.42%
7Years 6.95%
10Years 6.18%
7.72% ROIC
7.72%
Averages
1Year 7.72%
3Years 8.09%
5Years 9.31%
7Years 8.77%
10Years 7.91%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Thermo Fisher Scientific Inc.
image
8b8b7b7b6b6b5b5b4b4b3b3b2b2b1b1b0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 6.34 B
Depreciation & Amortization 3.11 B
Capital Expenditures -1.4 B
Stock-Based Compensation 301 M
Change in Working Capital -334 M
Others 129 M
Free Cash Flow 7.27 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Thermo Fisher Scientific Inc.
image
Wall Street analysts predict an average 1-year price target for TMO of $635 , with forecasts ranging from a low of $585 to a high of $693 .
TMO Lowest Price Target Wall Street Target
585 USD 33.60%
TMO Average Price Target Wall Street Target
635 USD 45.13%
TMO Highest Price Target Wall Street Target
693 USD 58.27%
Price
Max Price Target
Min Price Target
Average Price Target
700700650650600600550550500500450450400400May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.07% DIVIDEND YIELD
0.43 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.601.601.401.401.201.201.001.000.800.800.600.600.400.400.200.200.000.000.150.150.150.170.190.220.260.30.350.390.430.150.150.150.170.190.220.260.30.350.390.150.150.150.170.190.220.260.30.350.390.150.600.150.600.150.600.170.680.190.760.220.880.261.040.31.200.351.400.391.560.432015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Thermo Fisher Scientific Inc.
image
Sold
0-3 MONTHS
33.8 M USD 7
3-6 MONTHS
53.4 M USD 3
6-9 MONTHS
32.3 M USD 5
9-12 MONTHS
54.5 M USD 4
Bought
0 USD 0
0-3 MONTHS
11 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Thermo Fisher Stock Benefits From the Launch of Krios 5 Cryo-TEM TMO launches the Krios 5 Cryo-TEM, boosting productivity and performance with enhanced automation. zacks.com - 2 weeks ago
Is it Worth Retaining Thermo Fisher Stock in Your Portfolio Now? TMO continues to hold on to investors' attention due to its value-added acquisitions and trusted end-market channels. zacks.com - 2 weeks ago
Thermo Fisher Scientific Launches the Krios 5 Cryo-Transmission Electron Microscope (TEM), Boosting Productivity and Performance With Enhanced Automation WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific™ Krios™ 5 Cryo-TEM. This next-generation, atomic-resolution platform leverages enhanced optics and AI-enabled automation to study molecular structures and interactions at a throughput and fidelity that was previously unattainable. A Leap Forward in Imaging and Insight In the rapidly evolving field of structural biology, single particle analysis (SPA) and cryo-elec. businesswire.com - 2 weeks ago
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 23, 2025 WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2025 before the market opens on Wednesday, April 23, 2025, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The. businesswire.com - 2 weeks ago
Thermo Fisher Scientific Launches First More Sustainable Large-Capacity and Superspeed Centrifuges with Next-Generation Natural Refrigerant Cooling System WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, introduced today new lines of floor-model centrifuges to provide more sustainable solutions without compromising performance and sample security. The Thermo Scientific™ Cryofuge™, Thermo Scientific™ BIOS and Thermo Scientific™ LYNX centrifuges are the first floor-model centrifuges that feature natural refrigerant cooling systems compliant with European Union (E.U.) and U.S. Environmental Protect. businesswire.com - 2 weeks ago
Thermo Fisher's New Deal With CZ Imaging Institute May Boost Its Stock TMO and CZ Imaging Institute to collaborate on further understanding of human cells. zacks.com - 3 weeks ago
Biohazard Bags Report 2025-2030 Featuring Thermo Fisher Scientific, Bel-Art, International Plastics, Cole-Parmer, Medegen, Tufpak, Capitol Scientific, Abdos Life Science, Tilak Polypack, Desco Medical Dublin, March 28, 2025 (GLOBE NEWSWIRE) -- The "Biohazard Bags Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering. globenewswire.com - 3 weeks ago
Thermo Fisher Scientific and Chan Zuckerberg Institute for Advanced Biological Imaging Collaborate to Further Understanding of Human Cells WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, has announced a Technology Alliance Agreement with the Chan Zuckerberg Institute for Advanced Biological Imaging (CZ Imaging Institute). This agreement aims to develop new technologies to enable researchers to better visualize human cells, significantly advancing scientific research and discovery. Cryo-electron microscopy (cryo-EM) is an essential tool in disease research and creating lifesaving. businesswire.com - 3 weeks ago
TMO Stock Set to Gain From the Launch of New Vulcan Automated Lab Thermo Fisher introduces the Vulcan Automated Lab to transform semiconductor analysis. zacks.com - 1 month ago
Thermo Fisher Scientific Introduces the Vulcan™ Automated Lab to Transform Semiconductor Analysis WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced the launch of the Thermo Scientific Vulcan™ Automated Lab, a groundbreaking solution designed to drive a new era of process development and control in semiconductor manufacturing. The seamlessly integrated system is designed to enhance productivity, increase yield and reduce operating costs for semiconductor manufacturers. The rapid evolution and min. businesswire.com - 1 month ago
Buy Two Ideal March 'Safer' Dividend Dogs Of 34 Barron's 2025 Pro-Picks Barron's New-Year (NY) Roundtable (RT) selections published in three issues 1/13-27/2025, listed 34 dividend picks as the best of 2025. Analysts predict top picks like AdvanSix, Applied Materials, and Salesforce could net significant returns, with an average gain estimate of 28.85%. Two standout "safer" stocks, AT&T and Annaly Capital, meet the dogcatcher ideal, offering high yields relative to their prices. seekingalpha.com - 1 month ago
Thermo Fisher Scientific: Strong Q4, Strategic M&A, And Poised For Growth In Life Sciences Thermo Fisher Scientific's Q4'24 and FY'24 results exceeded expectations, with revenue and profitability growing, positioning it for a potential 12% IRR long-term. Strong capital allocation, including $4.6 billion returned to shareholders and strategic acquisitions, supports Thermo Fisher's growth and undervalued stock potential. Despite weak guidance, Thermo Fisher's leadership in life sciences and pharma, along with expected 11% CAGR earnings growth, indicates a solid long-term outlook. seekingalpha.com - 1 month ago
8. Profile Summary

Thermo Fisher Scientific Inc. TMO

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 165 B
Dividend Yield 0.07%
Description Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Contact 168 Third Avenue, Waltham, MA, 02451 https://www.thermofisher.com
IPO Date March 17, 1980
Employees 125000
Officers Mr. Gianluca Pettiti Executive Vice President and President of Life Science, Diagnostics & Applied Mr. Stephen Williamson Senior Vice President & Chief Financial Officer Mr. Michel Lagarde Executive Vice President & Chief Operating Officer Mr. Rafael Tejada Vice President of Investor Relations Mr. Michael A. Boxer Esq. Senior Vice President & General Counsel Ms. Lisa P. Britt Chief Human Resources Officer & Senior Vice President Mr. Joseph R. Holmes Vice President & Chief Accounting Officer Mr. Marc N. Casper Chairman, President & Chief Executive Officer Mr. Ryan J. Snyder Senior Vice President & Chief Information Officer Dr. Karen E. Nelson Ph.D. Chief Scientific Officer